Voyager Therapeutics (VYGR) AI Stock Analysis

• Market Cap: $218.51M
• Dividend Yield: N/A
• Average Volume (3M): 630.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: -80.88%
• EPS Growth: -388.61%
• Country: US
• Employees: 172
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 55,600,082
• 10 Day Avg. Volume: 467,023
• 30 Day Avg. Volume: 630,191
• PEG Ratio: 0.04
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 4.09
• P/FCF Ratio: -17.36
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: 3.32
• Enterprise Value/Gross Profit: 3.32
• Enterprise Value/Ebitda: -0.78
• 1Y Price Target: $13.57
• Price Target Upside: 230.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $4.00 ▼(-2.68% Downside)

The overall stock score of 46 reflects significant financial performance challenges, including declining revenues and profitability issues. Technical analysis indicates bearish momentum, and the negative P/E ratio highlights valuation concerns. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Strategic Collaborations

The collaboration with Transition Bio enhances Voyager's pipeline with potential treatments for ALS and FTD, leveraging innovative biomolecular approaches, which could lead to significant long-term revenue through milestone payments and royalties.

Cash Runway

Having a cash runway until 2028 provides financial stability and flexibility, allowing Voyager to focus on long-term strategic goals without immediate pressure to raise additional capital.

Innovative Platforms

The launch of the NeuroShuttle platform represents a significant innovation in nonviral delivery systems, potentially enhancing Voyager's competitive edge in gene therapy for neurological diseases.

Negative Factors

Revenue Decline

The significant decline in revenue poses a challenge to Voyager's financial health, potentially impacting its ability to invest in R&D and maintain competitive positioning in the biotechnology sector.

Profitability Issues

Ongoing profitability challenges, indicated by negative margins, may hinder Voyager's ability to reinvest in its business and sustain long-term growth, affecting overall financial performance.

Cash Flow Concerns

Insufficient cash flow generation to cover net income raises liquidity concerns, potentially limiting Voyager's operational flexibility and ability to fund future growth initiatives.

Voyager Therapeutics Business Overview & Revenue Model

Company Description

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Voyager Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments tied to the achievement of specific development goals, and royalties on product sales. Additionally, the company may receive funding from grants or government programs aimed at advancing research in gene therapy. Their revenue model is heavily dependent on the successful progression of their clinical trials and the commercialization of their therapies, as well as maintaining strong relationships with industry partners to enhance their product pipeline and potential market reach.

Voyager Therapeutics Financial Statement Overview

Summary

Voyager Therapeutics faces challenges in achieving consistent revenue growth and profitability, with negative profit margins and fluctuating cash flow metrics. Despite a low debt-to-equity ratio, the company needs to improve its return on equity and stabilize cash flows to enhance financial health.

Income Statement

Voyager Therapeutics has experienced significant revenue volatility, with a notable decline in revenue growth rate of -36.41% in the TTM period. The company maintains a high gross profit margin of 100%, but this is overshadowed by negative net profit, EBIT, and EBITDA margins, indicating ongoing operational challenges and profitability issues.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio of 0.165 in the TTM period, suggesting manageable leverage. However, the negative return on equity of -37.65% indicates that the company is not generating returns for shareholders. The equity ratio is not provided, but the overall financial position appears stable with room for improvement in profitability.

Cash Flow

Voyager Therapeutics has a positive free cash flow to net income ratio of 1.02 in the TTM period, indicating some efficiency in cash generation relative to net income. However, the operating cash flow is negative, and the free cash flow growth rate has fluctuated significantly, reflecting instability in cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	31.32M	80.00M	250.01M	40.91M	37.41M	171.13M
Gross Profit	31.32M	80.00M	157.84M	-14.86M	-36.37M	62.38M
EBITDA	-133.40M	-78.56M	126.45M	-39.65M	-68.45M	31.20M
Net Income	-126.78M	-65.00M	132.33M	-46.41M	-71.20M	36.74M
Balance Sheet
Total Assets	288.31M	393.05M	351.28M	159.36M	193.85M	261.58M
Cash, Cash Equivalents and Short-Term Investments	208.93M	266.68M	230.88M	118.85M	132.54M	181.14M
Total Debt	38.37M	43.73M	20.29M	23.13M	44.18M	47.61M
Total Liabilities	68.49M	93.29M	114.96M	100.34M	98.80M	107.26M
Stockholders Equity	219.82M	299.76M	236.32M	59.02M	95.06M	154.32M
Cash Flow
Free Cash Flow	-118.86M	-18.83M	74.66M	-15.00M	-55.13M	-108.81M
Operating Cash Flow	-116.73M	-15.31M	77.92M	-12.51M	-53.52M	-96.72M
Investing Cash Flow	50.82M	-94.86M	-141.64M	-7.34M	65.91M	113.00M
Financing Cash Flow	1.25M	114.02M	33.65M	1.11M	612.00K	3.16M

Voyager Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.11
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYGR, the sentiment is Negative. The current price of 4.11 is below the 20-day moving average (MA) of 4.42, below the 50-day MA of 4.54, and above the 200-day MA of 3.80, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 41.10 is Neutral, neither overbought nor oversold. The STOCH value of 24.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VYGR.

Voyager Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLN	54 Neutral	$307.49M	-3.89	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VYGR	46 Neutral	$218.51M	―	-46.09%	―	-80.88%	-388.61%
RNAC	41 Neutral	$200.48M	-0.15	―	―	―	―
TNYA	36 Underperform	$224.91M	-1.44	-96.44%	―	―	46.68%
KYTX	36 Underperform	$275.04M	-1.73	-70.82%	―	―	-21.22%
GALT	35 Underperform	$363.22M	-8.81	―	―	―	18.82%

Voyager Therapeutics Corporate Events

Voyager Therapeutics Reports Increased Losses Amid Rising R&D Costs

Voyager Therapeutics, Inc. is a biotechnology company focused on developing gene therapies for neurological diseases, leveraging its proprietary platforms to address conditions such as Alzheimer’s and Parkinson’s disease. In its latest earnings report for the quarter ending September 30, 2025, Voyager Therapeutics disclosed a net loss of $27.9 million, reflecting an increase from the previous year’s loss of $9 million for the same period. The company’s collaboration revenue decreased significantly, from $24.6 million in the third quarter of 2024 to $13.4 million in 2025, while operating expenses rose due to increased research and development costs. Despite these challenges, Voyager Therapeutics maintains a robust cash position with $229 million in cash, cash equivalents, and marketable securities, which the company believes will support its operations for at least the next twelve months. Looking ahead, Voyager Therapeutics remains committed to advancing its pipeline and strategic collaborations, aiming to enhance its position in the gene therapy market for neurological diseases.

Voyager Therapeutics Advances Alzheimer’s Study with VY7523

Voyager Therapeutics Inc. is conducting a study titled VY7523-102: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Ascending Intravenous Doses of VY7523 in Participants With Early Alzheimer’s Disease. The study aims to assess the safety and effectiveness of VY7523, a new drug for treating early Alzheimer’s Disease, by comparing its effects to a placebo.

Voyager Therapeutics Joins Citi’s Biopharma Conference 2025

Voyager Therapeutics announced its participation in Citi’s 2025 Biopharma Back to School Conference, highlighting its strategic advancements in neurotherapeutics. The company aims to optimize the delivery of therapeutics to the central nervous system through its innovative platforms, and anticipates significant clinical milestones in the coming years. This announcement underscores Voyager’s commitment to advancing its pipeline and strengthening its industry position, supported by substantial non-dilutive funding and collaborations.

The most recent analyst rating on (VYGR) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Voyager Therapeutics stock, see the VYGR Stock Forecast page.

Voyager Therapeutics Extends Cash Runway to 2028

Voyager Therapeutics, Inc. is a biotechnology company focused on using genetic approaches to treat neurological diseases, with a notable presence in the Alzheimer’s disease research sector. In its second quarter 2025 earnings report, Voyager Therapeutics highlighted its extended cash runway into 2028, the addition of a new APOE program to its Alzheimer’s disease pipeline, and the potential for significant milestone payments from its partnered programs. Key financial metrics showed a decrease in collaboration revenue to $5.2 million from $29.6 million year-over-year, while research and development expenses slightly decreased, and the company reported a net loss of $33.4 million for the quarter. Despite the financial challenges, Voyager’s strategic focus remains on advancing its clinical programs, with expectations to have four programs in the clinic by next year. Looking ahead, Voyager Therapeutics is positioned to reach multiple clinical milestones, supported by its strong cash position and strategic partnerships, as it continues to pursue advancements in neurotherapeutics.